

# COVID-19 Intel Report


Prepared for the IFPMA, BIO and DCVMN Press Briefing  
All data is property of Airfinity

---

# 16<sup>th</sup> December 2021

# Significant progress made in 2021 on COVID-19 vaccines

An overview of major milestones achieved to date



# Despite a big increase in vaccination rates there are concerns on variants and rising cases

An analysis of the current dominant variant, infections, deaths and vaccinations globally over time


50% 100%




Omicron dominant



Delta dominant



No data/non-VoC/VoI dominant




82




Countries with at least one confirmed omicron case


Cases globally



Deaths globally




People vaccinated (per 100)




# Vaccine production forecast to hit 11.2bn doses in 2021, with a capacity of 1.4bn in December alone

## Vaccine production split by candidate



# China, EU, India and the US set to be the biggest vaccine producers in 2021


Vaccine production split by country




# If a variant-updated vaccine is needed, production rate in 2022 would slow initially

An analysis of production forecasts if rate continues or if 50% of production is diverted to producing a variant vaccine

### Production scale up if production continues at the current rate





### Production scale up if 50% of production in 2022 is diverted to producing a variant updated vaccine\*



# Significant increase seen in donations, either direct or through COVAX

Deliveries of vaccines through COVAX or through direct donations over time


- COVAX supply secured directly
- Country contributions to COVAX
- Bilateral donations (from one country to another)




# Significant impact on protection against infection from omicron, awaiting more data on hospitalisations and boosters

Comparison of vaccine effectiveness against different variants

Protection against symptomatic infection\*




Protection against hospitalisation\*



Estimated protection against symptomatic infection restored from boosters

- Overall
- Delta
- Omicron





Booster data: [UKHSA study](#)  
 Pfizer/BNT Omicron hospitalisation data: [Discovery Health study](#)  
 All other data: Airfinity vaccine performance tool  
 Visualisation: Airfinity

Data on vaccine effectiveness against Omicron is extremely limited and based on a very small number of studies so should be interpreted with caution. This slide summarises what is currently published.




# Promising COVID-19 vaccine candidates in the pipeline

## Overview of candidates and clinical trial phase






Variant updated vaccines : 4  
 Alternative route of administration: 2  
 Able to store in fridge: 13  
 Able to store at room temperature: 1



# Lots of innovation expected in 2022 for COVID-19 vaccines

A summary of vaccines in the pipeline



## Copyright Notice and Disclaimer

---

### → Copyright notice

All intellectual property rights in this publication and the information published herein are the exclusive property of Airfinity and may only be used under licence from Airfinity.


Without limiting the foregoing, by accessing this publication you agree that you will not copy or reproduce or recirculate or distribute or use any part of its contents in any form or for any purpose whatsoever except under valid licence from Airfinity. Unauthorised distribution is strictly prohibited.

### → Disclaimer

The data and other information published herein are provided on an "as is basis". Airfinity makes no warranties, express or implied, as to the accuracy, adequacy, timeliness, or completeness of the data or fitness for any particular purpose. Airfinity shall not be liable for any loss, claims or damage arising from any party's reliance on the data and disclaim any and all liability relating to or arising out of use of the data to the full extent permissible by law.

# Airfinity forecasts have been realistic to observed production

Comparison of Airfinity forecasts (made in early February) vs observed production up until July



## Appendix

### Other vaccines mentioned in the production forecast

---

#### Other vaccines include

COVIran Barekat (Shifa Pharmed)  
CoviVac (Chumakov Federal Scientific Center)  
CoVLP (Medicago/GSK)  
EpiVacCorona (VECTOR)  
FINLAY-FR-2 (Finlay Vaccine Institute)  
GRAd-COV2 (Reithera/LeukoCare/Univercells )  
INO-4800 (Inovio Pharma)  
LUNAR-COV19 (Arcturus)  
MVC-COV1901 (Medigen/Dynavax)  
NVX-CoV2373 (Novavax)  
QazCovid-in (RI for Biological Safety Problems)  
Razi Cov Pars (Razi Vaccine and Serum Research Institute)  
S-268019 (Shionogi)  
SCB-2019 (Clover/Dynavax)  
UB-612 (Covaxx/Vaxxinity)  
Vaccine (Sanofi/GSK)  
VLA2001 (Valneva/Dynavax)  
ZF2001 (Anhui Zhifei)  
ZyCoV-D (Zydus Cadila)  
Ad5-nCoV (CanSino)  
CIGB-66 (Center for Genetic Engineering and Biotechnology (CIGB))

## Appendix

### Definitions for types of production

---

**Definitions:****Source of materials:**

Public announcements to supply raw materials for vaccine candidates

**Distribution and storage:**

Public announcements to distribute and/or store vaccines after production (separate from procurement deal)

**Adjuvant:**

Public announcements to produce and supply adjuvant for vaccine formulations

**Fill and finish:**

Public announcements to fill and finish vaccines into vials and syringes

**Tech:**

Public announcements to produce active vaccines or vaccine components.

## Studies included in the Airfinity vaccine meta effectiveness tool

Omicron study:

<https://khub.net/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+Omicron+variant+of+concern.pdf/f423c9f4-91cb-0274-c8c5-70e8fad50074>

**Number of studies used in Airfinity Meta analysis**

	Pfizer-BNT	AstraZeneca	Moderna	J&J
Overall effectiveness	47	17	20	15
Effectiveness against Delta	16	8	9	2
Effectiveness against hospitalisations	16	5	10	11
Effectiveness against Delta hospitalisations	11	5	4	2

In this scenario it is assumed that vaccine production is reduced by 50% for 3 months to implement production of a new variant-specific vaccine, then there is an exponential increase in Omicron-specific vaccine production over the following 3 months, bringing production back to a rate of 1.4 billion doses produced per month. Following this period, vaccine production continues at a constant rate equal to the rate at the end of 2021 (current rate). Here the total production of vaccines is separated by the cumulative production of vaccines targeting wild-type Covid-19 and Omicron-specific vaccines.



---

# More info.

→ Press

Sarah Harper

Media and Communications Manager

+44 777 365 9099

[sarah@airfinity.com](mailto:sarah@airfinity.com)